NCT00402727已完成3 期
A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 813
- 主要终点
- Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population
研究概览
简要总结
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the secretions or tissue around their infection site. In addition, the site of the infection will be photographed. The patients will be randomly assigned one of the treatments: intravenous (IV)/per oral (PO) moxifloxacin (drug under evaluation) or IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid (i.e., one of the reference treatments for this kind of infection). The maximum treatment duration will be 21 days, and the minimum will be 7 days. During the hospitalization, the patients will have a physical examination every day. On Day 3-5 during therapy as well as at the end of treatment, the patients will have repeated examinations. These tests and evaluations will be repeated 14 to 28 days after the end of treatment. During this visit, blood and urine samples will be taken only if judged necessary by the physicians.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Men or women of 18 years and above with a diagnosis of bacterial skin and skin structure infection that requires
- •Hospitalization and
- •Initial parenteral therapy for at least 48 hours and
- •Meets at least one of the following criteria:
- •Involvement of deep soft tissue (e.g. fascial, muscle layers)
- •Requirement for a significant surgical intervention including surgical drainage, drainage procedure guided by imaging and/or debridement
- •Association with a significant underlying disease that may complicate response to treatment. An underlying disease is considered significant if it includes any of the following conditions that are present at the time of presentation: cancer (except basal- or squamous-cell cancer of the skin), cardiac (i.e., congestive heart disease), diabetes mellitus, hepatic (i.e., cirrhosis or another form of chronic liver disease), immunologic, renal disease, respiratory, transplantation or vascular disease
- •Duration of infection < 21 days
- •Diagnosis of one of the following skin and skin structure infections that requires hospitalization and initial parenteral antibiotic therapy for at least 48 hours:
- •Major abscess(es) associated with extensive cellulitis, which requires antibiotic therapy in addition to surgical incision and drainage
- •Diabetic foot infection of mild to severe intensity (perfusion, extent/size, depth/tissue loss, infection and sensation (PEDIS) grade 2-4) in the presence or absence of osteomyelitis. Subjects with osteomyelitis may only be enrolled if the infected bone is completely removed by surgery and if residual infection requiring antibiotics is still present following surgery
- •Wound infection including: post surgical (surgical incision), post-traumatic, human bite/clenched fist and animal bite wound and wound associated with injection drug abuse:
- •Infections must have occurred within 30 days of a surgical procedure, trauma, animal bite, or human bite, and involve the skin and skin structures at the site of the incision, trauma, or bite
- •In addition, post-surgical/trauma wound infections must meet the following criteria:
- •Involvement of deep soft tissues (e.g. fascial and muscle layers) of the incision/trauma
- •At least one of the following criteria:
- •Purulent drainage from the deep incision/trauma
- •Identification of an infecting organism from an aseptically obtained culture of fluid or tissue from incision/trauma
- •At least one of the following signs and symptoms:
- •Localized pain or tenderness
- •Fever (see below) AND the incision (in case of post-surgical wound infections) is deliberately opened by a surgeon, unless the culture is negative
- •Abscess or other evidence of infection involving the deep incision/trauma, found on direct examination, during reoperation/operation (in case of trauma), or by histologic or radiologic examination
- •Diagnosis of a deep incisional/post-trauma Skin Structure Infections (SSI) by a surgeon or attending physician
- •Bite wounds/clenched fist infections and wounds associated with injection drug abuse must meet the criteria defining a Complicated Skin and Skin Structure Infections (cSSSI)
- •Infected ischemic ulcers with at least one of the following conditions:
- •Peripheral vascular disease
- •Conditions pre-disposing to pressure sores such as paraplegia, peripheral neuropathy
- •Presence of at least 3 of the following signs or symptoms:
- •Purulent drainage or discharge
- •Erythema extending > 1 cm from the wound edge
- •Fluctuance
- •Pain or tenderness to palpation
- •Swelling or induration
- •Fever, defined as body temperature
- •> 37.5°C (axillary)
- •> 38°C (orally)
- •> 38.5°C (tympanically) or
- •> 39°C (rectally)
- •Elevated total peripheral white blood cell (WBC) count > 12,000/mm3 or
- •>15 % immature neutrophils (bands) regardless of total peripheral WBC count
- •C reactive protein (CRP) >20 mg/L
- •Specimen obtained for culture from infected area by needle aspiration of obviously purulent material or by tissue biopsy or by curettage of the surface of ulcer within 48 hours prior to the initiation of study drug therapy
- •Duration of treatment of the skin/skin structure infection is anticipated to be at least 7 days.
- •Surgical drainage or debridement of infected wounds or abscesses, if necessary, have to have been completed <= 48 hours after the initiation of study drug therapy
排除标准
- •Women, who are pregnant or lactating, or in whom pregnancy can not be excluded (Note: a urine pregnancy test has to be performed for all women of childbearing potential before randomization to the study drug)
- •The following skin and skin structure infections:
- •Necrotizing fasciitis including Fourniers gangrene, ecthyma gangrenosum, streptococcal necrotizing fasciitis and clostridial necrotizing fasciitis
- •Burn wound infections
- •Secondary infections of a chronic skin disease (e.g. atopic dermatitis)
- •Infection of prosthetic materials (e.g. subcutaneous tissue infection related to a central venous catheter or permanent cardiac pacemaker battery pack). Subjects with removal of a prosthetic device involved in an infection should not be included
- •Infections where a surgical procedure alone is definitive therapy
- •Subjects with uncomplicated skin and skin structure infections including folliculitis and furunculosis, carbunculosis, simple abscesses and superficial cellulitis
- •Known hypersensitivity to quinolones and/or any type of beta-lactam antibiotic drugs or any of the excipients
- •Previous history of cholestatic jaundice/hepatic dysfunction associated with amoxicillin-clavulanic acid
- •Severe, life threatening disease with a life expectancy of less than 2 months
- •Immunosuppression including:
- •Known neutropenia (neutrophil count < 1000/µL)
- •Known lymphopenia with absolute CD4+ T cell count < 200/mm3
- •Acquired immunodeficiency syndrome (AIDS)-defining event and/or concomitant therapy with Highly Active Antiretroviral Therapy (HAART)
- •Chronic treatment (>/= 2 weeks) with known immunosuppressant therapy (including treatment with > 15 mg/day of systemic prednisone or equivalent)
- •Any other congenital or acquired immune defect or immunosuppression
- •Known severe hepatic insufficiency (Child Pugh C) or transaminases increase > 5 fold upper limit of normal (ULN)
- •Known renal impairment with a baseline measured or calculated serum creatinine clearance < 40 mL/min
- •Known prolongation of the QT interval or concomitant use of drugs reported to increase the QT interval (e.g. Class IA or Class III antiarrhythmics [eg., quinidine, procainamide, amiodarone, sotalol], neuroleptics [e.g. haloperidol], tricyclic antidepressive agents, certain antimicrobials [e.g. pentamidine, halofantrine], certain antihistaminics [e.g. terfenadine], and other [cisapride, vincamine IV, depridil, diphemanil])
- •Uncorrected hypokalemia
- •Clinically relevant bradycardia
- •Clinically relevant heart failure with reduced left ventricular ejection fraction (i.e., below 40%)
- •Previous history of symptomatic arrhythmias
- •Previous history of tendon disease/disorder with quinolones
- •Known or suspected concomitant bacterial infection requiring additional systemic antibacterial treatment, e.g. underlying septic arthritis
- •Requiring therapy with probenecid
- •Treatment with a systemic or topical antibacterial agent for > 24 hours in the previous 7 days preceding study entry unless the subject showed no response or had worsening of clinical signs and symptoms despite 3 or more days of prior therapy and a culture obtained at the time of subject enrollment showed persistence of a pathogen which is susceptible to the study drugs. The prior antimicrobial therapy must not have been a fluoroquinolone or a beta lactam/beta lactamase combination
- •Infection known to be due to a Methicillin-Resistant Staphylococcus Aureus (MRSA), Methicillin-Resistant Staphylococcus Epidermidis (MRSE) or Vancomycin Resistant Enterococcus (VRE) as the single isolated pathogen
- •Previous enrolment in this study
- •Participation in any clinical investigational drug study within 4 weeks of screening
- •Previous history of seizure disorders
研究组 & 干预措施
Moxifloxacin
Experimental
Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
干预措施: Moxifloxacin (Avelox, BAY12-8039) (Drug)
PIP/TAZ-AMC
Active Comparator
Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
干预措施: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid (Drug)
结局指标
主要结局
Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Per Protocol (PP) Population
时间窗: 14 - 28 days after last dose of study medication
Clinical response was evaluated by the DRC and graded as "cure", "failure" or "indeterminate" at the TOC visit. Members of the DRC were provided with subject data from the study database that included clinical signs and symptoms at each visit, concomitant medication, microbiology results, laboratory tests and interpretation of photographs.
次要结局
- Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the ITT Population With Causative Organisms(after 7 - 21 days of treatment)
- Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Per Protocol (PP) Population(after 7 - 21 days of treatment)
- Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the Microbiological Valid (MBV) Population(3 - 5 days after start of treatment)
- Percentage of Cured Participants as Determined by the Data Review Committee (DRC) at Test of Cure Visit in the Intent to Treat (ITT) Population(14 - 28 days after last dose of study medication)
- Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Per Protocol (PP) Population(3 - 5 days after start of treatment)
- Percentage of Participants With Bacteriological Success (BS) at 3 to 5 Days After Start of Treatment in the ITT Population With Causative Organisms(3 - 5 days after start of treatment)
- Percentage of Participants Assessed as Improvements by the Data Review Committee (DRC) at the During Treatment Day 3-5 in the Intent to Treat (ITT) Population(3 - 5 days after start of treatment)
- Percentage of Participants Assessed as Resolution by the Data Review Committee (DRC) at End of Therapy in the Intent to Treat (ITT) Population(after 7 - 21 days of treatment)
- Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the Microbiological Valid (MBV) Population(14 - 28 days after last dose of study medication)
- Percentage of Participants With Bacteriological Success (BS) After 7 - 21 Days of Treatment in the Microbiological Valid (MBV) Population(after 7 - 21 days of treatment)
- Percentage of Participants With Bacteriological Success (BS) After 14 - 28 Days After Last Dose of Study Medication in the ITT Population With Causative Organisms(14 - 28 days after last dose of study medication)
研究者
相似试验
已完成
2 期
Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaMixed DyslipidemiaNCT04998201Arrowhead Pharmaceuticals353
Unknown
不适用
Effect of a Mixture of Fibers and Carbohydrates on Intestinal Transit in Children Diagnosed With Functional ConstipationConstipation - FunctionalNCT04028258Laboratorios Ordesa120
撤回
不适用
Steroid Injections Given at the "Level of MRI Pathology" Versus at the "Level of Clinical Symptoms" to See if One is More Effective Than the Other.RadiculopathyIntervertebral Disc DisplacementSpinal StenosisNCT02196883State University of New York - Upstate Medical University
已完成
不适用
Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus InfectionAbscessMethicillin-Resistant Staphylococcus Aureus InfectionNCT0082269259th Medical Wing139
已完成
不适用
Study of a Cold Sore Patch for the Treatment of Herpes LabialisHerpes LabialisNCT01484067Johnson & Johnson Consumer Products Company Division of Johnson & Johnson Consumer Companies, Inc.472